Skip to main navigation
Skip to search
Skip to main content
University of Arizona Home
Home
Profiles
Departments and Centers
Scholarly Works
Activities
Grants
Datasets
Prizes
Search by expertise, name or affiliation
Limited Stage Aggressive Non-Hodgkin Lymphoma: What Is Optimal Therapy?
Abhijeet Kumar
, Srinath Sundararajan
, Soham Puvvada
, Daniel O. Persky
Medicine
Research output
:
Contribution to journal
›
Review article
›
peer-review
3
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Limited Stage Aggressive Non-Hodgkin Lymphoma: What Is Optimal Therapy?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Immunology and Microbiology
B Cell
50%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Germinal Center
50%
Positron Emission Tomography-Computed Tomography
100%
Radiation Field
50%
Rituximab
100%
X-Ray Computed Tomography
50%
Medicine and Dentistry
B Cell
16%
Chemoimmunotherapy
16%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
33%
Diffuse Large B-Cell Lymphoma
16%
Disease
100%
Germinal Center
16%
Non-Hodgkin Lymphoma
100%
Positron Emission Tomography
16%
Positron Emission Tomography-Computed Tomography
33%
Radiation Therapy
16%
Radioimmunotherapy
16%
Rituximab
33%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
33%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
33%
Diffuse Large B Cell Lymphoma
16%
Disease
100%
Nonhodgkin Lymphoma
100%
Rituximab
33%
Keyphrases
Aggressive NHL
20%
Disease Subsets
20%